Wockhardt recalls over 109,000 bottles of hypertension drug in US

Tags: Wockhardt
Drugmaker Wockhardt Ltd is recalling 109,744 bottles of a high blood pressure drug in the United States after it failed a dissolution test, the US Food and Drug Administration said.

The recall of metoprolol succinate began in April and was posted on the FDA website late Wednesday. Metoprolol succinate extended release is a cheaper generic form of AstraZeneca Plc's branded drug Toprol.

A Wockhardt spokesman did not immediately respond to a request for comment on Thursday.

Dissolution tests are commonly conducted to check the time taken for the active ingredient in a drug to release into the body, and help predict how the drug performs inside the body.

Recalls of medicines by drugmakers are not uncommon, but Wockhardt is already embroiled in regulatory troubles.

Two of its manufacturing plants were banned last year from exporting to the United States after the FDA found violations of manufacturing standards that the agency believed could compromise the quality of drugs. One of those plants was making metoprolol succinate for the United States.

The FDA website said the recalled lots were manufactured at a Wockhardt plant in Mumbai.

EDITORIAL OF THE DAY

  • India’s political space acts as a safety valve for maverick politicians and frustrated electorate

    While it is easy to be cynical about Indian democracy and its ways, the fact is that the vast political space that the system provides for in this cou

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Taslima Nasreen

Bangladesh no country for atheists

It’s a matter of pride to be a freethinker, atheist ...

Purnendu Ghosh

Silence makes you aware of yourself

Often, we don’t feel the necessity of making contact with ...

Shona Adhikari

Artistic focus on women's empowerment

The focus on the girl child remains an important one ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture